Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tackles long COVID's hidden heart and nerve symptoms

NCT ID NCT06305780

Disease control Sponsor: Kanecia Obie Zimmerman Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tested different treatments for autonomic dysfunction, including POTS, in 381 adults with Long COVID. It compared non-drug approaches and medications to see which best eased symptoms like rapid heart rate and dizziness. The goal was to find effective ways to manage these lingering issues after a COVID-19 infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

381 people

The number who actually took part.

Started

Mar 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥ 18 years of age at the time of enrollment 2. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization12ɸ ɸ Enrollment of participants with suspected or probable SARS-CoV-2 infection will only be allowed if they occurred before May 1, 2021 and be limited to no more than 10% of the total sample size per Study Drug Appendix. Refer to the Manual of Procedures (MOP) for details. Suspected case of SARS-CoV-2 infection - Three options, A through C: A. Meets the clinical OR epidemiological criteria. 1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. 2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test. Probable case of SARS-CoV-2 infection, defined as meets clinical criteria above AND is a contact of a probable or confirmed case or is linked to a COVID-19 cluster. Confirmed case of SARS-CoV-2 infection - Two options, A through B: A. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Meeting clinical criteria AND/OR epidemiological criteria (See suspect case A). With a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test. 3. Moderate, self-identified autonomic symptoms (defined as COMPASS-31 \>20) following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent 4. OHQ/OIQ, question 1 score \>2 Exclusion Criteria: 1. Known pregnancy, breast-feeding, or contemplating pregnancy during the study period 2. Known active acute SARS-CoV-2 infection ≤ 4 weeks from enrollment 3. Known renal failure (eGFR \<20ml/1.73 m²) 4. Known atrial fibrillation or significant cardiac arrhythmia 5. Known cardiovascular conditions such as heart failure (Class 3-4), severe valvular disease 6. Clinically significant atherosclerotic disease, defined as history of stroke or myocardial infarction or revascularization 6 months prior to enrollment and/or current symptomatic angina 7. Existing uncontrolled hypertension 8. Inability to comply with the protocol 9. Any condition that the investigator believes makes it inappropriate to treat with study intervention, including severe debility. 10. History of POTS or significant dysautonomia before COVID-19 index infection 11. Enrolled in another clinical trial or another study intervention appendix in this platform protocol \* Patients who are a part of observational studies (e.g. imaging) may be included in this trial. Participants may enroll in another interventional trial or re-enroll in this trial for a different study intervention appendix 30 days after end of study (Follow-up visit).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dysautonomia long COVID-19 postural orthostatic tachycardia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID Long COVID-19 Long COVID19

Contacts and locations

Locations

  • Bateman Horne Center - Appendix B Only

    Salt Lake City, Utah, 84102, United States

  • Brigham and Women's Hospital - Appendix A Only

    Boston, Massachusetts, 02115, United States

  • Cedars Sinai Medical Center - Appendix A & B

    Los Angeles, California, 90048, United States

  • Center for Complex Neurology - Appendix A & B

    Phoenix, Arizona, 85006, United States

  • Cleveland Clinic - Appendix A & B

    Cleveland, Ohio, 44195, United States

  • Columbia University Irving Medical Center - Appendix A & B

    New York, New York, 10032, United States

  • Duke University Hospital - Appendix A & B

    Durham, North Carolina, 27710, United States

  • East Alabama Medical Center - Appendix B Only

    Opelika, Alabama, 36801, United States

  • East Carolina University - Appendix B Only

    Greenville, North Carolina, 27834, United States

  • Evergreen Hospital Medical Center - Appendix A & B

    Kirkland, Washington, 98034, United States

  • Grady Memorial Hospital - Woodruff Memorial Research - Appendix A & B

    Atlanta, Georgia, 30303, United States

  • Henry Ford Hospital - Appendix A & B

    Detroit, Michigan, 48202, United States

  • Innovation Clinical Trials Inc.- Appendix A & B

    Palmetto Bay, Florida, 33157, United States

  • Johns Hopkins Hospital - Appendix A Only

    Baltimore, Maryland, 21287, United States

  • Kent Hospital - Appendix A & B

    Pawtucket, Rhode Island, 02860, United States

  • Lakeland Regional Medical Center - Appendix A & B

    Lakeland, Florida, 33805, United States

  • Marshall Health - University Physicians and Surgeons - Appendix A & B

    Huntington, West Virginia, 25701, United States

  • Mayo Clinic - Appendix A & B

    Rochester, Minnesota, 55905, United States

  • MedStar National Rehabilitation Hospital - Appendix B only

    Washington D.C., District of Columbia, 20010, United States

  • Montefiore Medical Center - Moses Campus - Appendix B

    The Bronx, New York, 10467, United States

  • Morehouse School of Medicine - Appendix A & B

    Atlanta, Georgia, 30310, United States

  • National Neuromuscular Research Institute - Appendix A & B

    Austin, Texas, 78759, United States

  • NorthShore University HealthSystem - Evanston Hospital - Appendix B Only

    Evanston, Illinois, 60201, United States

  • Oregon Health and Science University - Appendix A & B

    Portland, Oregon, 97239, United States

  • Providence Medical Research Center - Appendix A & B

    Spokane, Washington, 99204, United States

  • Queens Medical Center - Appendix B Only

    Honolulu, Hawaii, 96813, United States

  • Rush University Medical Center - Appendix B Only

    Chicago, Illinois, 60612, United States

  • Sentara Norfolk General Hospital - Appendix A & B

    Norfolk, Virginia, 23507, United States

  • Southwest Family Medicine Associates - Appendix A & B

    Dallas, Texas, 75235, United States

  • St. Lawrence Health Medical Campus - Appendix A & B

    Canton, New York, 13617, United States

  • Stanford University - Appendix B Only

    Stanford, California, 94305, United States

  • Stony Brook University Hospital - Appendix A & B

    Stony Brook, New York, 11794, United States

  • University Medical Center New Orleans - Appendix A & B

    New Orleans, Louisiana, 70112, United States

  • University at Buffalo - Appendix A & B

    Buffalo, New York, 14203, United States

  • University of Arkansas for Medical Sciences - Appendix A & B

    Little Rock, Arkansas, 72205, United States

  • University of California San Diego - Appendix B Only

    La Jolla, California, 92307, United States

  • University of Colorado Anschutz Medical Campus Clinical and Translational Research Center (CTRC) - Appendix A & B

    Aurora, Colorado, 80045, United States

  • University of Florida Health - Appendix A & B

    Gainesville, Florida, 32610, United States

  • University of Illinois at Chicago - Appendix A & B

    Chicago, Illinois, 60612, United States

  • University of Iowa - Appendix A & B

    Iowa City, Iowa, 52242, United States

  • University of Kansas Medical Center CTSU Fairway - Appendix A & B

    Fairway, Kansas, 66205, United States

  • University of Kentucky Medical Center - Appendix A & B

    Lexington, Kentucky, 40536, United States

  • University of Mississippi Medical Center - Appendix A & B

    Jackson, Mississippi, 39216, United States

  • University of Oklahoma Health Science Center - Oklahoma Clinical and Translational Science Institute - Appendix A & B

    Oklahoma City, Oklahoma, 73104, United States

  • University of Texas Health Science Center at Houston

    Houston, Texas, 78701, United States

  • University of Texas Health Science Center at San Antonio - Appendix A & B

    San Antonio, Texas, 78229, United States

  • University of Virginia Health System, University Hospital - Appendix A & B

    Charlottesville, Virginia, 22908, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Vermont Lung Center, University of Vermont - Appendix B Only

    Burlington, Vermont, 05405, United States

  • Washington University School of Medicine - Appendix B Only

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.